MOHW to approve NHI reimbursement for Iressa.

Published: 2004-02-11 07:00:00

Updated: 2004-02-11 07:00:00

The MOHW finally approved Iressa, a non-small cell lung cancer drug, for the NHI reimbursement in the 2nd NHI policy review panel on Feb. 6 for the treatment of non small cell lung cancer and the gamma knife operation of brain tumors. Accordingly, the NHI reimbursement will be granted from Mar. 1...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK